These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23538634)

  • 21. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial.
    Sengupta S; Venkatesh R; Ravindran RD
    J Glaucoma; 2012 Sep; 21(7):450-9. PubMed ID: 21543993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular changes after intra-bleb injection of bevacizumab.
    Coote MA; Ruddle JB; Qin Q; Crowston JG
    J Glaucoma; 2008; 17(7):517-8. PubMed ID: 18854726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.
    Jeong JH; Chun YS; Kim ES; Kim JC
    Cornea; 2011 Oct; 30(10):1071-7. PubMed ID: 21775887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.
    Petsoglou C; Balaggan KS; Dart JK; Bunce C; Xing W; Ali RR; Tuft SJ
    Br J Ophthalmol; 2013 Jan; 97(1):28-32. PubMed ID: 23087419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY; Kim MK; Wee WR
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
    Zaki AA; Farid SF
    Cornea; 2009 Oct; 28(9):986-8. PubMed ID: 19724215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX; Bahar I; Levinger E; Rootman D
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
    Chu HS; Hu FR; Yang CM; Yeh PT; Chen YM; Hou YC; Chen WL
    Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.
    Acar BT; Halili E; Acar S
    Int Ophthalmol; 2013 Oct; 33(5):507-13. PubMed ID: 23404727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary results of subconjunctival bevacizumab in primary pterygium excision.
    Razeghinejad MR; Hosseini H; Ahmadi F; Rahat F; Eghbal H
    Ophthalmic Res; 2010; 43(3):134-8. PubMed ID: 19887878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study.
    Lekhanont K; Patarakittam T; Thongphiew P; Suwan-apichon O; Hanutsaha P
    Cornea; 2012 Feb; 31(2):155-61. PubMed ID: 22081150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.
    Foroutan A; Fariba B; Pejman B; Mahmoud J; Khalil GF; Arash EA; Foroutan P
    Cornea; 2010 Nov; 29(11):1268-72. PubMed ID: 20802316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intralesional bevacizumab use for invasive ocular surface squamous neoplasia.
    Paul S; Stone DU
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):647-9. PubMed ID: 22900896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subconjunctival bevacizumab in the impending recurrent pterygia.
    Bayar SA; Kucukerdonmez C; Oner O; Akova YA
    Int Ophthalmol; 2014 Jun; 34(3):541-7. PubMed ID: 24026871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial.
    Shenasi A; Mousavi F; Shoa-Ahari S; Rahimi-Ardabili B; Fouladi RF
    Cornea; 2011 Nov; 30(11):1219-22. PubMed ID: 21955635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of intralesional bevacizumab injection in decreasing pterygium size.
    Fallah Tafti MR; Khosravifard K; Mohammadpour M; Hashemian MN; Kiarudi MY
    Cornea; 2011 Feb; 30(2):127-9. PubMed ID: 20885313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.